Reviva Pharmaceuticals (RVPH) to Release Earnings on Monday

Reviva Pharmaceuticals (NASDAQ:RVPH) is projected to issue its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.0543) per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, March 30, 2026 at 4:00 PM ET.

Reviva Pharmaceuticals Trading Down 5.4%

Shares of RVPH stock opened at $0.74 on Friday. Reviva Pharmaceuticals has a 52 week low of $0.67 and a 52 week high of $23.20. The company has a market cap of $4.78 million, a PE ratio of -0.08 and a beta of 0.10. The company’s fifty day simple moving average is $4.27 and its 200-day simple moving average is $7.92.

Wall Street Analyst Weigh In

RVPH has been the topic of several recent research reports. Wall Street Zen raised Reviva Pharmaceuticals to a “sell” rating in a research report on Saturday, March 14th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. D. Boral Capital cut shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. Chardan Capital restated a “buy” rating and issued a $40.00 target price on shares of Reviva Pharmaceuticals in a research note on Monday, January 5th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Thursday, January 22nd. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Reviva Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $66.67.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Several large investors have recently modified their holdings of the stock. NewEdge Advisors LLC acquired a new stake in shares of Reviva Pharmaceuticals in the 1st quarter worth about $58,000. Geode Capital Management LLC raised its holdings in Reviva Pharmaceuticals by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after buying an additional 29,063 shares during the period. Millennium Management LLC lifted its holdings in shares of Reviva Pharmaceuticals by 15.0% in the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after purchasing an additional 223,178 shares in the last quarter. Armistice Capital LLC purchased a new stake in shares of Reviva Pharmaceuticals in the second quarter worth approximately $1,026,000. Finally, State Street Corp grew its stake in Reviva Pharmaceuticals by 202.4% in the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after purchasing an additional 256,500 shares in the last quarter. Institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.